vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与莱迪思半导体（LSCC）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是莱迪思半导体的1.0倍（$152.6M vs $145.8M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -5.2%，领先39.8%），莱迪思半导体同比增速更快（24.2% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $44.0M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 1.8%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
莱迪思半导体是美国专注于低功耗现场可编程门阵列（FPGA）设计制造的半导体企业，1983年成立，1989年上市，总部位于俄勒冈州希尔斯伯勒硅林区，在圣何塞、上海、马尼拉、槟城、新加坡等地设有运营网点，截至2022年员工超1000人，年营收超6.6亿美元。
CPRX vs LSCC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $145.8M |
| 净利润 | $52.7M | $-7.6M |
| 毛利率 | 82.9% | 68.5% |
| 营业利润率 | 40.5% | 0.7% |
| 净利率 | 34.5% | -5.2% |
| 营收同比 | 7.6% | 24.2% |
| 净利润同比 | -5.8% | -146.3% |
| 每股收益（稀释后） | $0.40 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $145.8M | ||
| Q4 25 | $152.6M | — | ||
| Q3 25 | $148.4M | $133.3M | ||
| Q2 25 | $146.6M | $124.0M | ||
| Q1 25 | $141.4M | $120.2M | ||
| Q4 24 | $141.8M | $117.4M | ||
| Q3 24 | $128.7M | $127.1M | ||
| Q2 24 | $122.7M | $124.1M |
| Q1 26 | — | $-7.6M | ||
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $2.8M | ||
| Q2 25 | $52.1M | $2.9M | ||
| Q1 25 | $56.7M | $5.0M | ||
| Q4 24 | $55.9M | $16.5M | ||
| Q3 24 | $43.9M | $7.2M | ||
| Q2 24 | $40.8M | $22.6M |
| Q1 26 | — | 68.5% | ||
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | 67.9% | ||
| Q2 25 | 85.9% | 68.4% | ||
| Q1 25 | 87.3% | 68.0% | ||
| Q4 24 | 84.7% | 61.1% | ||
| Q3 24 | 85.0% | 69.0% | ||
| Q2 24 | 87.4% | 68.3% |
| Q1 26 | — | 0.7% | ||
| Q4 25 | 40.5% | — | ||
| Q3 25 | 44.7% | -1.2% | ||
| Q2 25 | 45.2% | 3.8% | ||
| Q1 25 | 44.8% | 5.8% | ||
| Q4 24 | 44.3% | -10.4% | ||
| Q3 24 | 39.6% | 5.9% | ||
| Q2 24 | 44.2% | 18.2% |
| Q1 26 | — | -5.2% | ||
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | 2.1% | ||
| Q2 25 | 35.6% | 2.3% | ||
| Q1 25 | 40.1% | 4.2% | ||
| Q4 24 | 39.4% | 14.1% | ||
| Q3 24 | 34.1% | 5.7% | ||
| Q2 24 | 33.2% | 18.2% |
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.42 | $0.02 | ||
| Q2 25 | $0.41 | $0.02 | ||
| Q1 25 | $0.45 | $0.04 | ||
| Q4 24 | $0.44 | $0.12 | ||
| Q3 24 | $0.35 | $0.05 | ||
| Q2 24 | $0.33 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $133.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $714.1M |
| 总资产 | $1.1B | $883.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $133.9M | ||
| Q4 25 | $709.2M | — | ||
| Q3 25 | $689.9M | $117.9M | ||
| Q2 25 | $652.8M | $107.2M | ||
| Q1 25 | $580.7M | $127.6M | ||
| Q4 24 | $517.6M | $136.3M | ||
| Q3 24 | $442.3M | $124.3M | ||
| Q2 24 | $375.7M | $109.2M |
| Q1 26 | — | $714.1M | ||
| Q4 25 | $954.3M | — | ||
| Q3 25 | $920.2M | $706.4M | ||
| Q2 25 | $856.0M | $687.0M | ||
| Q1 25 | $794.3M | $707.9M | ||
| Q4 24 | $727.6M | $710.9M | ||
| Q3 24 | $660.9M | $703.5M | ||
| Q2 24 | $608.7M | $698.8M |
| Q1 26 | — | $883.1M | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $844.4M | ||
| Q2 25 | $971.9M | $808.6M | ||
| Q1 25 | $908.9M | $823.6M | ||
| Q4 24 | $851.4M | $843.9M | ||
| Q3 24 | $772.0M | $853.7M | ||
| Q2 24 | $706.4M | $827.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $57.6M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $44.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 30.2% |
| 资本支出强度资本支出/营收 | 0.0% | 9.3% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $132.6M |
8季度趋势，按日历期对齐
| Q1 26 | — | $57.6M | ||
| Q4 25 | $44.9M | — | ||
| Q3 25 | $32.4M | $47.1M | ||
| Q2 25 | $71.3M | $38.5M | ||
| Q1 25 | $60.0M | $31.9M | ||
| Q4 24 | $70.9M | $45.4M | ||
| Q3 24 | $72.9M | $44.0M | ||
| Q2 24 | $64.1M | $21.9M |
| Q1 26 | — | $44.0M | ||
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | $71.3M | $31.3M | ||
| Q1 25 | — | $23.3M | ||
| Q4 24 | $70.8M | $39.7M | ||
| Q3 24 | $72.6M | $39.4M | ||
| Q2 24 | $64.1M | $14.8M |
| Q1 26 | — | 30.2% | ||
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | 25.5% | ||
| Q2 25 | 48.6% | 25.2% | ||
| Q1 25 | — | 19.4% | ||
| Q4 24 | 49.9% | 33.8% | ||
| Q3 24 | 56.4% | 31.0% | ||
| Q2 24 | 52.3% | 11.9% |
| Q1 26 | — | 9.3% | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 9.8% | ||
| Q2 25 | 0.0% | 5.8% | ||
| Q1 25 | 0.0% | 7.2% | ||
| Q4 24 | 0.1% | 4.9% | ||
| Q3 24 | 0.2% | 3.7% | ||
| Q2 24 | 0.0% | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | 16.86× | ||
| Q2 25 | 1.37× | 13.23× | ||
| Q1 25 | 1.06× | 6.35× | ||
| Q4 24 | 1.27× | 2.75× | ||
| Q3 24 | 1.66× | 6.12× | ||
| Q2 24 | 1.57× | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
LSCC
| Asia | $106.3M | 73% |
| Americas | $21.0M | 14% |
| Europe | $18.5M | 13% |
